Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 141 - 150 of 243
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Mona Lisa N.V.
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Innova Quality S.A.S
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Delivery Method: Subdermal
Developer: Shandong University
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Nestorone (NES) + Estradiol (E2) Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: NICHD, Population Council
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Nestorone (NES) Single Rod Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Population Council
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Nestorone + Testosterone Gel
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Nestorone (NES) Metered Dose Transdermal System® (MDTS®)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Population Council, Acrux, Ltd., Fempharm Pty Ltd.
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Nestorone (NES) + Estradiol (E2) Transdermal Gel
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Antares, Population Council
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 21 - 30 of 70
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Prototype Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Alternative Name: Inhibition of Vas Propulsive Contractility
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: King's College, London
Development Stage: Lead Optimization
Alternative Name: K4K20S4
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other, Other
Development Stage: Lead Optimization
Alternative Name: Plasma Membrane Calcium ATPase (PMCA) Inhibitors
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: University of Manchester, Max Planck Institute
Alternative Name: Electrospun fiber meshes
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Development Stage: Prototype Development
User: Male
Hormonal: No
Duration Type: Long-acting
Delivery Method: Vas Deferens
Developer: Contraline, LLC
Development Stage: Lead Optimization
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development

Pages

Displaying 31 - 40 of 121
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Alternative Name: Single Rod GES Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Phase III
Alternative Name: GES VR
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Pre-clinical

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV